Quality of life in patients with advanced gastroesophageal (GE) adenocarcinoma treated with modified docetaxel, cisplatin, and fluorouracil (mDCF)

被引：0
|
作者：
Smyth, E. C.
Janjigian, Y. Y.
Robinson, E.
Sheehy, E. C.
Karpenko, I.
Capanu, M.
Kelsen, D. P.
Shah, M. A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial
    Kelsen, D.
    Jhawer, M.
    Ilson, D.
    Tse, A.
    Randazzo, J.
    Robinson, E.
    Capanu, M.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
    Shah, Manish A.
    Jhawer, Minaxi
    Ilson, David H.
    Lefkowitz, Robert A.
    Robinson, Edric
    Capanu, Marinela
    Kelsen, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 868 - 874
  • [3] Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group
    Ajani, Jaffer A.
    Moiseyenko, Vladimir M.
    Tjulandin, Sergei
    Majlis, Alejandro
    Constenla, Manuel
    Boni, Corrado
    Rodrigues, Adriano
    Fodor, Miguel
    Chao, Yee
    Voznyi, Edouard
    Awad, Lucile
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) : 3210 - 3216
  • [4] The importance of thiol/disulphide homeostasis in patients with advanced gastric cancer (AGC) receiving modified docetaxel and cisplatin plus fluorouracil (mDCF) regimen
    Yazici, O.
    Ozdemir, N.
    Erel, O.
    Demirci, N. S.
    Aksoy, S.
    Sendur, M. A. N.
    Dogan, M.
    Yazilitas, D.
    Erdem, G. U.
    Neselioglu, S.
    Hocazade, C.
    Bozkaya, Y.
    Bal, O.
    Zengin, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S468 - S469
  • [5] Random assignment multicenter phase II studyof modified docetwel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE)
    Shah, M. A.
    Shibata, S.
    Stoller, R. G.
    Kemeny, M.
    Ritch, P. S.
    Krishnamurthi, S. S.
    Su, Y. B.
    Janjigian, Y. Y.
    Capanu, M.
    Kelsen, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC)
    Onitilo, Adedayo A.
    Stankowski-Drengler, Trista J.
    Shiyanbola, Oyewale
    Engel, Jessica
    Tanimu, Sabo
    Fagbemi, Seth O.
    Li, Ya-Huei
    CLINICAL MEDICINE & RESEARCH, 2021, 19 (02) : 64 - 71
  • [7] Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
    Ajani, JA
    Fodor, MB
    Tjulandin, SA
    Moiseyenko, VM
    Chao, Y
    Filho, SC
    Cabral, S
    Majlis, A
    Assadourian, S
    Van Cutsem, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5660 - 5667
  • [8] Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer?
    Gihan Ratnayake
    David Cunningham
    Nature Clinical Practice Oncology, 2008, 5 : 132 - 133
  • [9] Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer?
    Ratnayake, Gihan
    Cunningham, David
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (03): : 132 - 133
  • [10] Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma
    Kim, S.
    Paget-Bailly, S.
    Messager, M.
    Nguyen, T.
    Mathieu, P.
    Lamfichekh, N.
    Fein, F.
    Fratte, S.
    Cleau, D.
    Lakkis, Z.
    Jary, M.
    Sakek, N.
    Jacquin, M.
    Foubert, A.
    Bonnetain, F.
    Mariette, C.
    Fiteni, F.
    Borg, C.
    EJSO, 2017, 43 (01): : 218 - 225
12345